Table 1:
Recent professional urological society guidelines on the use of focal therapy in localized renal cell carcinoma.
| Society | Year | Recommendation |
|---|---|---|
| American Society of Clinical Oncology (ASCO) | 2017 | Percutaneous thermal ablation should be considered an option if complete ablation can reliably be achieved.a |
| American Urological Association (AUA) | 2021 | Physicians should consider thermal ablation for cT1a renal masses < 3 cm.b |
| European Association of Urology (EAU) | 2021 | Offer active surveillance or thermal ablation (TA) to frail and/or comorbid patients with small renal masses. Do not routinely offer TA for tumors > 3 cm and cryoablation for tumors > 4 cm.c |
| National Comprehensive Care Network (NCCN) | 2022 | Thermal ablation is an option for patients with cT1 disease, but may be associated with higher rates of recurrence or persistence in tumors > 3 cm.d |
a
Level of evidence – moderate; bLevel of evidence – conditional recommendation, grade C; cLevel of evidence – weak; dLevel of evidence – 2A.